Altamira Therapeutics AG is developing and supplying peptide-based nanoparticle technologies for efficient nucleic acid delivery to extrahepatic tissues (xPhore™ platform). The versatile delivery platform is suited for different nucleic acid modalities, including siRNA, mRNA, circRNA, as well as DNA, and made available to pharma or biotech companies through out-licensing.

Altamira Medica AG is commercializing Bentrio®, a drug-free and preservative-free nasal spray for the prophylaxis and treatment of allergic rhinitis.

Otolanum AG is developing CNS therapeutics, primarily for neurological and inner ear disorders.